Last quarter (Q2 2022), Zylox-Tonbridge Medical Technology Co., Ltd. Class H's total revenue was $―, a decrease of ― from previous quarter. In Q2, Zylox-Tonbridge Medical Technology Co., Ltd. Class H's net income was $―. See Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19
Total Revenue	$ ―	$ 177.91M	$ 27.63M	$ 4.92M
Cost of Revenue	$ ―	$ 46.03M	$ 11.34M	$ 3.73M
Gross Profit	$ ―	$ 131.88M	$ 16.29M	$ 1.19M
Operating Expense	$ ―	$ 349.94M	$ 113.51M	$ 70.14M
Operating Income	$ ―	$ -218.06M	$ -97.23M	$ -68.94M
Net Non Operating Interest Income Expense	$ ―	$ 12.79M	$ -306.00K	$ -946.00K
Other Income Expense	$ ―	$ ―	$ ―	$ ―
Pretax Income	$ ―	$ -199.69M	$ -100.47M	$ -66.65M
Tax Provision	$ ―	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -199.69M	$ -100.47M	$ -66.65M
Basic EPS	$ ―	$ -0.68	$ -0.31	$ -0.21
Diluted EPS	$ ―	$ -0.68	$ -0.31	$ -0.21
Basic Average Shares	$ ―	$ 294.60M	$ 323.40M	$ 323.40M
Diluted Average Shares	$ ―	$ 294.60M	$ 323.40M	$ 323.40M
Dividend Per Share	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ 395.97M	$ 124.86M	$ 73.86M
Net Income From Continuing And Discontinued Operation	$ ―	$ -199.69M	$ -100.47M	$ -66.65M
Normalized Income	$ ―	$ -213.63M	$ -100.47M	$ -69.57M
Interest Expense	$ ―	$ 307.00K	$ 666.00K	$ 1.03M
EBIT	$ ―	$ -199.38M	$ -99.80M	$ -65.61M
EBITDA	$ ―	$ -186.00M	$ -90.16M	$ -56.04M

Currency in USD

Zylox-Tonbridge Medical Technology Co., Ltd. Class H Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing